$$\rightleftharpoonup{xx}$$
$$\longleftharp{xx}$$,
$$\longrightharp{xx}$$,
The overall goal of this method is to apply dynamic contrast enhanced magnetic resonance imaging (DCE-MRI) for orthotopic pancreatic tumor xenografts in mice. DCE-MRI is a non-invasive method to assess microvasculature in a target tissue by monitoring the change of MR contrast over a certain period of time after injection. DCE-MRI has been utilized to diagnose malignant tumors and to assess tumor response to various therapies1-4. Quantitative DCE-MRI has presented high reproducibility5. To quantitate pharmacokinetic parameters of an MR contrast agent in a target tissue, all DCE-MR images acquired at different time points and T1 map obtained before contrast injection must be coregistered6. However, due to respiratory and peristaltic motions in the abdominal area, quantitative DCE-MRI has had limited application for gastrointestinal tumors.
Orthotopic pancreatic tumor models have been utilized to assess pancreatic-tumor response following biological therapies and chemotherapies7,8. Orthotopic tumor models are considered superior to conventional subcutaneous models, since the microenvironment in the original tumor site is reflected and thereby human tumor response to therapy can be more accurately predicted. However, the mouse pancreas is located in the left upper quadrant of the abdomen, so quantitative DCE-MRI of orthotopic pancreatic tumor xenografts in mice has not been readily implemented.
We have established a protocol of DCE-MRI of abdominal tumors in mice by fixing the tumors using an orthogonally bent plastic board to prevent motion transfer from the chest region9. The pressure applied by this board was localized on the abdominal area, and has not resulted in respiratory difficulty. An automated image coregistration technique has been validated for DCE-MRI of abdominal organs in a free-breathing mode, but it performs effectively only when the target regions move slowly and regularly10. Respiratory rate of animals is variable during imaging, so physical restraint in the abdominal area will be necessary to retrieve reliable pharmacokinetic parameters in orthotopic pancreatic tumor mouse models. We have successfully quantitated the pharmacokinetic parameters of an MR contrast agent in orthotopic pancreatic tumor xenografts using the orthogonally bent plastic board in DCE-MRI11-13. Here we present the detailed procedure of orthotopic pancreatic tumor modeling, DCE-MRI of the tumor xenografts in mice, and quantification of pharmacokinetic parameters.